Biontech, a spinout of Johannes Gutenberg University Mainz, has received $91.5m in funding as part of the extension of a deal to develop a cancer immunotherapy candidate with Sanofi.

Pharmaceutical firm Sanofi has made an €80m ($91.5m) equity investment in Germany-based immuno-oncology therapy developer Biontech in connection with the extension of a research and development collaboration agreement.
Spun out of Johannes Gutenberg University Mainz in 2008, Biontech is developing immunotherapies to treat cancer and infectious diseases. It formed a research partnership with Sanofi in 2015 and the companies plan to team up on the development and commercialisation of a cancer immunotherapy candidate.
Another pharmaceutical firm, Pfizer, had…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.

Not sure if you have a subscription?